AKR7A2

Across TCGA pan-cancer cohorts, AKR7A2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AKR7A2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AKR7A2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AKR7A2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where AKR7A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.855	0.563	.008	22	view →
LUAD	DFS	Tertile	II,III,IV	0.607	0.945	.006	14	view →
PDAC	OS	Quartile	All	0.620	0.418	.030	8	view →
UCEC	OS	Quartile	II,III,IV	0.364	1.000	.010	4	view →
LSCC	DFS	Median	II,III,IV	0.862	0.965	.030	1	view →
HNSC	DFS	Quartile	III,IV	1.000	0.873	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AKR7A2–CCRCC (DFS)

Open the CCRCC breakdown →